OMEGA THERAPEUTICS INC (OMGA) Fundamental Analysis & Valuation
NASDAQ:OMGA • US68217N1054
Current stock price
0.1426 USD
-0.02 (-10.82%)
At close:
0.11 USD
-0.03 (-22.86%)
After Hours:
This OMGA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. OMGA Profitability Analysis
1.1 Basic Checks
- In the past year OMGA has reported negative net income.
- In the past year OMGA has reported a negative cash flow from operations.
- OMGA had negative earnings in each of the past 5 years.
- In the past 5 years OMGA always reported negative operating cash flow.
1.2 Ratios
- OMGA has a Return On Assets of -47.86%. This is comparable to the rest of the industry: OMGA outperforms 48.17% of its industry peers.
- Looking at the Return On Equity, with a value of -633.21%, OMGA is doing worse than 80.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| ROIC | N/A |
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- OMGA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. OMGA Health Analysis
2.1 Basic Checks
- OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- OMGA has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for OMGA has been reduced compared to a year ago.
2.2 Solvency
- OMGA has an Altman-Z score of -4.95. This is a bad value and indicates that OMGA is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of OMGA (-4.95) is worse than 60.73% of its industry peers.
- OMGA has a Debt/Equity ratio of 1.00. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 1.00, OMGA is doing worse than 78.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.95 |
ROIC/WACCN/A
WACC9.59%
2.3 Liquidity
- A Current Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
- OMGA's Current ratio of 1.61 is on the low side compared to the rest of the industry. OMGA is outperformed by 80.80% of its industry peers.
- A Quick Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
- The Quick ratio of OMGA (1.61) is worse than 79.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 |
3. OMGA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 36.06% over the past year.
- The Revenue has grown by 184.04% in the past year. This is a very strong growth!
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
3.2 Future
- Based on estimates for the next years, OMGA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.60% on average per year.
- The Revenue is expected to grow by 150.92% on average over the next years. This is a very strong growth
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
3.3 Evolution
4. OMGA Valuation Analysis
4.1 Price/Earnings Ratio
- OMGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMGA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as OMGA's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%
5. OMGA Dividend Analysis
5.1 Amount
- No dividends for OMGA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OMGA Fundamentals: All Metrics, Ratios and Statistics
0.1426
-0.02 (-10.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners81.36%
Inst Owner Change0%
Ins Owners1.4%
Ins Owner Change0%
Market Cap7.90M
Revenue(TTM)8.10M
Net Income(TTM)-73.09M
Analysts82.86
Price Target13.26 (9198.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.54%
PT rev (3m)40.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.68 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 118.3% | ||
| Cap/Sales | 25.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 | ||
| Altman-Z | -4.95 |
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A
OMEGA THERAPEUTICS INC / OMGA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of OMEGA THERAPEUTICS INC (OMGA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to OMGA.
What is the valuation status for OMGA stock?
ChartMill assigns a valuation rating of 1 / 10 to OMEGA THERAPEUTICS INC (OMGA). This can be considered as Overvalued.
What is the profitability of OMGA stock?
OMEGA THERAPEUTICS INC (OMGA) has a profitability rating of 0 / 10.
Can you provide the financial health for OMGA stock?
The financial health rating of OMEGA THERAPEUTICS INC (OMGA) is 1 / 10.
Can you provide the expected EPS growth for OMGA stock?
The Earnings per Share (EPS) of OMEGA THERAPEUTICS INC (OMGA) is expected to grow by 34.35% in the next year.